Pharmacogenomics: Identification of New Drug Targets
Dipeptidyl Peptidase 4 Inhibitors
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Inhibitors of Viral Protein Synthesis
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
您也可能阅读
通过共同作者、期刊和引用图与本文相关的文章。
Pradeep Natarajan1, Sekar Kathiresan1
1Center for Human Genetic Research and Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA 02114, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Harvard Medical School, Boston, MA 02115, USA.
阿利罗库马布和埃沃洛库马布是抑制PCSK9的单克隆抗体,增加LDL受体并降低LDL胆固醇. 这些疗法有效降低了LDL胆固醇,这是动脉样硬化心血管疾病的关键因素.
科学领域:
背景情况:
研究的目的:
主要方法:
主要成果:
结论: